hypertensive encephalopathy: Encephalopathy resulting from hypertension.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
155 |
4. Check minimum number of eventsNone |
155 |
5. Include endpointsNone |
155 |
6. Filter based on genotype QC (FinnGen only) |
138 |
Control definitions (FinnGen only)
- Control exclude
- I9_CEREBVASC
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- I67
- Name in latin
- Encephalopathia hypertensiva
Similar endpoints
↥List of similar endpoints to
Hypertensive encephalopathy
based on the number of shared cases.
Similar with more cases:
- Cerebrovascular diseases (FINNGEN)
- Cerebrovascular diseases
- Hypertension
- Hypertensive diseases (excluding secondary)
- Hypertensive diseases
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1060 | 561 | 482 |
| Only index persons | 823 | 460 | 363 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.02 | 0.01 |
| Only index persons | 0.02 | 0.02 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 67.18 | 71.76 | 61.86 |
| Only index persons | 66.77 | 72.24 | 59.83 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 138 | 69 | 69 |
| Unadjusted period prevalence (%) | 0.03 | 0.02 | 0.03 |
| Median age at first event (years) | 70.76 | 70.82 | 70.71 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 140
- Matched controls
- 1400
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
I67.4
ICD-10 Finland
Hypertensive encephalopathy
+∞
171.2
127
*
I63.9
ICD-10 Finland
Cerebral infarction, unspecified
124.3
35.7
37
*
I69.3
ICD-10 Finland
Sequelae of cerebral infarction
148.3
33.3
34
*
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
8.0
28.5
49
88
AA1AD
NOMESCO Finland
CT of head and brain
4.2
15.8
73
290
I67.3
ICD-10 Finland
Progressive vascular leukoencephalopathy
64.0
15.2
17
*
I63.3
ICD-10 Finland
Cerebral infarction due to thrombosis of cerebral arteries
166.7
14.8
15
*
G30.1
ICD-10 Finland
Alzheimer disease with late onset
5.3
14.3
34
80
4372A
ICD-9 Finland
Other and ill-defined cerebrovascular disease, Hypertensive encephalopathy
+∞
12.7
12
*
C08CA01
ATC
amlodipine; oral
3.4
10.9
89
479
N06DX01
ATC
memantine; oral
4.1
10.5
34
101
XA800
NOMESCO Finland
Neuropsychological investigation
20.8
10.5
15
8
I10
ICD-10 Finland
Essential (primary) hypertension
4.0
9.2
118
798
XF400
NOMESCO Finland
ECG with 12 standard connections
3.3
9.0
42
159
Z3226
NOMESCO Finland
Physiotherapist
3.3
8.8
43
167
TPH07
NOMESCO Finland
Cathetrisation of artery
3.9
8.8
30
92
Z01.9
ICD-10 Finland
Special examination, unspecified
4.9
8.7
21
49
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
5.0
8.7
20
45
205
Kela drug reimbursment
Chronic hypertension
2.9
8.5
65
325
Z2446
NOMESCO Finland
Social worker
5.3
8.4
18
38
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
4.4
8.4
23
60
B01AC30
ATC
platelet aggregation inhibitors excl. heparin - combinations
8.1
8.3
18
25
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.9
7.6
49
221
PA6BD
NOMESCO Finland
Extensive CT of neck arteries
14.4
7.5
12
9
Z2221
NOMESCO Finland
Medical doctor
2.8
7.4
51
239
I63.4
ICD-10 Finland
Cerebral infarction due to embolism of cerebral arteries
+∞
7.3
7
*
C03AA03
ATC
hydrochlorothiazide; oral
3.7
7.3
26
82
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.7
7.2
89
553
R56.8
ICD-10 Finland
Other and unspecified convulsions
7.0
7.2
17
27
R4110
NOMESCO Finland
Physiotherapy
2.6
6.9
55
275
ZXD10
NOMESCO Finland
Scheduled procedure
2.6
6.9
67
370
C07AB07
ATC
bisoprolol; oral
2.7
6.8
98
649
Z71.2
ICD-10 Finland
Person consulting for explanation of investigation findings
2.6
6.6
55
280
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
5.6
6.5
18
36
TKC20
NOMESCO Finland
Catheterisation of bladder
4.1
6.4
19
52
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
19.1
6.3
9
5
I67.1
ICD-10 Finland
Cerebral aneurysm, nonruptured
+∞
6.3
6
*
4019X
ICD-9 Finland
Essential hypertension, Unspecified
6.6
6.2
15
25
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
9.3
6.2
12
14
R5110, ,
SPAT
3.6
6.2
22
69
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
98
543
3.68
11.76
3.2
2.2
94.03
96.59
pmol/l
0.18
62
270
57
270
2.87
8.19
4.1
3.1
2.48
2.47
mmol/l
0.20
52
234
78
436
2.78
8.14
3.7
3.7
2.36
2.35
mmol/l
0.45
71
393
94
591
2.80
7.59
10.6
5.8
1.20
1.21
mmol/l
0.96
89
544
54
258
2.78
7.53
1.9
1.8
844.95
1256.12
nmol/l
3.19
38
191
72
402
2.63
7.31
2.1
1.7
18.21
22.59
nmol/l
2.19
67
321
24
75
3.66
6.80
2.0
1.6
—
—
—
0
0
96
657
2.47
5.79
14.6
6.4
1.20
1.21
mmol/l
0.43
87
557
80
519
2.26
5.28
3.0
2.6
76.23
79.39
nmol/l
0.40
75
451
60
350
2.25
5.08
3.0
2.2
2.99
3.09
mg/l
0.11
53
298
41
207
2.39
4.83
4.5
3.2
2.38
3.20
e6/l
0.23
20
105
115
894
2.60
4.66
11.4
8.3
87.36
82.03
u/l
0.30
110
838
8
9
9.34
4.34
1.4
1.0
—
—
—
0
0
32
152
2.43
4.27
9.3
6.5
4.62
5.04
kpa
1.65
32
146
32
152
2.43
4.27
9.3
6.5
11.17
11.69
kpa
0.27
32
147
16
52
3.34
4.24
1.6
4.2
1.26
4.63
ratio
1.15
11
23
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
13
31
4.51
4.13
1.5
2.5
0.26
0.34
iu/ml
—
5
21
41
220
2.22
4.13
4.5
3.1
0.77
1.09
e6/l
0.59
21
118
8
10
8.40
4.12
1.4
1.0
—
—
—
0
0
8
10
8.40
4.12
1.4
1.0
—
—
—
0
0
30
142
2.42
4.02
8.1
3.1
5.78
5.68
kpa
0.25
30
137
60
377
2.04
3.99
4.8
3.5
0.13
0.42
e6/l
2.52
47
280
43
245
2.09
3.68
2.3
1.9
—
—
—
0
0
18
71
2.76
3.45
1.5
1.4
—
—
—
0
0
120
1007
2.34
3.19
6.5
5.4
1.88
1.97
mu/l
0.35
114
904
6
8
7.77
3.08
1.7
2.0
—
—
—
0
0
6
8
7.77
3.08
1.3
1.1
1.80
1.88
mmol/l
—
6
8
87
659
1.85
3.04
11.4
9.5
4.12
4.30
e9/l
0.36
72
578
25
124
2.24
2.99
5.5
2.5
4.12
4.25
kpa
0.11
25
119
78
576
1.80
2.92
2.5
2.8
—
—
—
0
0
6
9
6.90
2.89
1.5
1.9
—
—
—
0
0
21
99
2.32
2.82
11.4
3.0
114.50
79.32
ng/l
1.10
21
85
5
6
8.58
2.77
2.6
2.0
—
—
—
0
0
9
25
3.77
2.62
3.8
2.4
3.20
3.20
g/l
—
9
25
31
176
1.98
2.62
2.5
1.9
—
—
—
0
0
7
16
4.54
2.51
1.4
1.1
—
—
—
0
0
48
320
1.76
2.46
3.4
2.8
397.76
361.47
umol/l
1.14
38
279
6
12
5.17
2.43
1.5
1.2
7.83
12.42
u/l
—
6
12
8
22
3.79
2.40
2.4
2.6
248.13
188.05
%
—
8
22
8
22
3.79
2.40
1.4
1.4
114.63
25.38
e6/l
—
8
16
18
86
2.25
2.35
8.8
6.2
24.95
24.80
mmol/l
0.06
18
86
29
168
1.92
2.31
2.7
2.0
—
—
—
0
0
11
42
2.75
2.20
1.3
1.1
—
—
—
0
0
5
11
4.67
1.96
1.6
1.4
12.00
13.45
u/l
—
5
11
58
431
1.59
1.89
5.5
4.2
16.18
8.81
mg/mmol
0.55
45
279
125
1124
2.05
1.88
42.0
22.8
138.96
139.55
mmol/l
1.45
125
1101
125
1124
2.05
1.88
42.4
22.9
3.98
4.01
mmol/l
0.47
125
1101
23
367
0.55
1.83
5.7
4.2
0.00
0.00
estimate
—
8
122
34
486
0.60
1.78
4.9
4.8
0.00
0.04
estimate
—
10
122
51
372
1.58
1.78
3.7
2.9
38.70
31.99
u/l
0.39
46
346
5
13
3.95
1.73
1.2
1.8
796.40
689.38
mg
—
5
13
16
83
2.05
1.73
9.8
8.2
0.99
1.57
%
1.64
16
83
122
1096
1.88
1.72
32.0
18.6
29.20
26.70
mg/l
0.30
111
936
11
49
2.35
1.68
1.7
1.7
—
—
—
0
0
7
26
2.78
1.60
1.7
1.1
—
—
—
0
0
7
26
2.78
1.60
1.7
1.1
—
—
—
0
0
125
1138
1.92
1.59
43.0
25.5
100.25
82.98
umol/l
1.99
125
1123
81
668
1.50
1.56
4.3
3.2
101.75
52.55
u/l
0.86
75
623
10
45
2.32
1.50
1.9
1.6
—
—
—
0
0
15
81
1.95
1.46
10.3
8.6
0.63
0.71
%
0.34
15
81
95
818
1.50
1.42
5.0
4.4
15.47
15.16
pmol/l
0.50
87
735
102
893
1.52
1.39
42.1
23.5
14.21
14.01
%
0.66
102
885
0
37
0.00
1.36
0.0
1.3
—
0.08
—
0
9
29
196
1.60
1.36
9.2
5.9
105.21
104.13
mmol/l
0.64
29
196
20
124
1.72
1.29
1.4
2.2
476.50
397.89
nmol/l
0.82
20
116
39
286
1.50
1.29
2.1
1.8
1.01
1.44
mg/l
1.05
31
234
17
101
1.78
1.26
2.2
1.5
—
—
—
0
0
8
36
2.29
1.26
1.3
1.4
—
—
—
0
0
118
1075
1.62
1.26
6.9
6.2
2.24
2.61
mmol/l
4.32
113
972
114
1031
1.57
1.25
9.2
7.2
40.36
40.53
mmol/mol
0.07
107
950
125
1156
1.76
1.25
46.8
28.1
91.99
91.58
fl
0.39
125
1142
125
1156
1.76
1.25
46.9
28.2
229.06
241.70
e9/l
1.29
125
1134
125
1156
1.76
1.25
48.2
28.6
38.54
39.53
%
1.52
125
1141
125
1156
1.76
1.25
46.9
28.1
4.27
4.38
e12/l
1.43
125
1128
26
368
0.64
1.23
4.6
4.6
0.00
0.01
estimate
—
8
136
125
1157
1.75
1.23
47.1
28.3
126.72
132.00
g/l
3.17
125
1142
38
281
1.48
1.20
2.6
2.5
—
—
—
0
0
7
31
2.32
1.12
1.3
1.5
—
—
—
0
0
6
29
2.12
0.90
1.7
1.0
—
—
—
0
0
11
65
1.75
0.85
12.6
3.6
1.56
1.41
%
0.36
11
60
57
478
1.32
0.84
3.8
3.4
3492.46
1690.82
ng/l
0.92
50
406
8
46
1.78
0.84
2.5
2.7
—
—
—
0
0
0
25
0.00
0.80
0.0
2.1
—
—
—
0
0
5
23
2.22
0.77
1.2
2.2
—
—
—
0
0
113
1052
1.38
0.76
6.9
5.6
6.26
6.10
mmol/l
0.50
105
942
5
26
1.96
0.71
1.2
1.4
—
—
—
0
0
5
27
1.88
0.69
1.4
2.1
—
—
—
0
0
71
629
1.26
0.65
4.5
4.7
0.00
0.00
estimate
-0.00
11
145
18
130
1.44
0.65
12.7
8.6
—
—
—
0
0
5
29
1.75
0.64
1.0
1.8
—
—
—
0
0
5
30
1.69
0.62
1.2
1.2
—
—
—
0
0
5
30
1.69
0.62
1.2
1.2
—
—
—
0
0
12
81
1.53
0.59
1.6
1.4
—
—
—
0
0
9
62
1.48
0.54
2.9
3.0
4.03
4.21
pmol/l
—
9
53
6
40
1.52
0.52
1.8
1.4
—
—
—
0
0
70
634
1.21
0.48
4.5
4.7
0.00
10.61
estimate
0.50
11
153
12
86
1.43
0.46
4.2
2.4
1.33
1.35
%
0.04
12
86
5
32
1.58
0.42
1.2
1.9
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
5
34
1.49
0.41
1.8
1.2
—
—
—
0
0
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
5
36
1.40
0.38
1.6
1.9
—
—
—
0
0
9
122
0.72
0.37
7.6
4.8
1.21
1.22
mmol/l
—
9
104
6
42
1.45
0.36
1.8
1.9
—
—
—
0
0
70
647
1.16
0.35
4.5
4.7
0.10
0.00
estimate
—
10
143
38
334
1.19
0.35
4.3
4.5
22.16
23.49
%
0.20
21
171
19
155
1.26
0.34
3.2
4.1
—
—
—
0
0
109
1045
1.19
0.33
5.8
5.4
4.07
4.51
mmol/l
3.87
101
946
108
1036
1.19
0.32
5.7
5.4
1.36
1.47
mmol/l
1.93
99
931
10
129
0.76
0.29
1.3
1.4
—
—
—
0
0
11
85
1.32
0.29
4.1
2.3
0.71
0.66
%
0.29
11
85
5
37
1.36
0.24
1.2
2.0
—
—
—
0
0
5
38
1.33
0.23
1.6
1.9
—
—
—
0
0
103
995
1.13
0.22
4.8
4.5
1.26
1.23
mmol/l
0.19
92
884
5
41
1.23
0.22
1.2
2.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
3.4
—
76.89
—
0
12
0
12
0.00
0.21
0.0
1.0
—
0.94
—
0
6
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
58
547
1.10
0.19
5.8
4.4
177.83
52.94
ng/l
0.39
44
421
16
138
1.18
0.18
1.3
1.5
—
—
—
0
0
5
67
0.74
0.17
4.2
3.1
1236.00
3395.60
u/ml
—
5
58
40
426
0.91
0.14
2.6
2.0
1.30
1.32
mmol/l
0.06
35
346
57
547
1.07
0.11
3.1
2.9
—
—
estimate
—
0
0
18
194
0.92
0.07
1.2
1.3
23.43
41.33
iu/ml
—
7
62
0
5
0.00
-0.00
0.0
1.0
—
40.38
—
0
5
0
5
0.00
-0.00
0.0
1.4
—
18.16
—
0
5
0
8
0.00
-0.00
0.0
1.0
—
686.75
—
0
8
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
5.6
—
1.00
—
0
8
0
8
0.00
-0.00
0.0
3.3
—
63.75
—
0
8
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.9
—
69.54
—
0
8
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
11.28
—
0
5
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
64.10
—
0
5
Mortality – FinRegistry
↥Association
Association between endpoint I9_HYPERTENC and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| I9_HYPERTENC | 1.734 [1.28, 2.34] | < 0.001 |
| Birth year | 0.994 [0.98, 1.0] | 0.144 |
During the follow-up period (1.1.1998 — 31.12.2019), 153 out of 379 females with I9_HYPERTENC died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| I9_HYPERTENC | 1.693 [1.05, 2.72] | 0.03 |
| Birth year | 0.986 [0.98, 1.0] | 0.003 |
During the follow-up period (1.1.1998 — 31.12.2019), 96 out of 273 males with I9_HYPERTENC died.
Mortality risk
Mortality risk for people of age
years, who have I9_HYPERTENC.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.233% | 0.273% |
| 5 | 1.208% | 1.923% |
| 10 | 2.592% | 4.794% |
| 15 | 4.882% | 8.678% |
| 20 | 8.622% | 14.586% |
Relationships between endpoints
↥Index endpoint: I9_HYPERTENC – Hypertensive encephalopathy
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data